# Immune Response to Influenza Vaccine in Adults With B-cell Malignancies Treated With Idelalisib

> **NCT03701438** · — · TERMINATED · sponsor: **Gilead Sciences** · enrollment: 2 (actual)

## Conditions studied

- B-cell Malignancies

## Interventions

- **BIOLOGICAL:** Influenza Vaccine

## Key facts

- **NCT ID:** NCT03701438
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2018-10-23
- **Primary completion:** 2019-10-09
- **Final completion:** 2019-10-09
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** The Swissmedic agency released Gilead from this post marketing requirement.
- **Last updated:** 2020-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03701438

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03701438, "Immune Response to Influenza Vaccine in Adults With B-cell Malignancies Treated With Idelalisib". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT03701438. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*